Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Key Points: 2-CdA is an effective treatment with a long-term acceptable safety profile in patients with mastocytosis. 2-CdA is effective and safe in indolent systemic mastocytosis and cutaneous mastocytosis refractory to multiple symptomatic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 2×
“Age at treatment’s initiation, y 54 (17-83) Time from diagnosis to treatment, mo 47 (1-473)”
MethodSelf-citationBodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.281 · Cited by 397 · cited 3×
“35-55 g/L 39 (57) 43 (35-53) Albumin ,35 8 (20) 30 (22.”
MethodSelf-citation
Cited by
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513098 · Cited by 488
Self-citationAnaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, J., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 347
Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Pardanani, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26962 · Cited by 132
“14 mg/kg via infusion or subcutaneously for 5 days) every 4–12 weeks up to 9 cycles.(118) The median num-”
Background
Metadata
- Authors
- Barete, S., Lortholary, O., Damaj, G., Hirsch, I., Chandesris, M. O., Elie, C., Hamidou, M., Durieu, I., Suarez, F., Grosbois, B., Limal, N., Gyan, E., Larroche, C., Guillet, G., Kahn, J. E., Casassus, P., Amazzough, K., Coignard-Biehler, H., Georgin-Lavialle, S., Lhermitte, L., Fraitag, S., Canioni, D., Dubreuil, P., & Hermine, O.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-08-20
- Volume
- 126
- Issue
- 8
- Pages
- 1009-1016
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1494664247
- Cited by
- 153
- References
- 2
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. https://app.cochat.ai/papers/10.1182/blood-2014-12-614743
- The paper
- Barete, S., Lortholary, O., Damaj, G., Hirsch, I., Chandesris, M. O., Elie, C., Hamidou, M., Durieu, I., Suarez, F., Grosbois, B., Limal, N., Gyan, E., Larroche, C., Guillet, G., Kahn, J. E., Casassus, P., Amazzough, K., Coignard-Biehler, H., Georgin-Lavialle, S., . . . Hermine, O. (2015). Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. https://doi.org/10.1182/blood-2014-12-614743
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.